40592-V08H86 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 98
    Sino Biological sars cov 2 2019 ncov spike rbd his recombinant protein covid 19 spike rbd research
    Sars Cov 2 2019 Ncov Spike Rbd His Recombinant Protein Covid 19 Spike Rbd Research, supplied by Sino Biological, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars cov 2 2019 ncov spike rbd his recombinant protein covid 19 spike rbd research/product/Sino Biological
    Average 98 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 2019 ncov spike rbd his recombinant protein covid 19 spike rbd research - by Bioz Stars, 2021-06
    98/100 stars
      Buy from Supplier

    97
    Sino Biological sars cov 2 rbd
    Histopathology and Immunohistochemistry of NHP lungs. (A) Pulmonary lesions depicting typical coronavirus respiratory pathology including locally extensive regions of bronchointerstitial pneumonia and proteinaceous fluid accumulation in adjacent alveoli (40x, H E). (B) Disseminated immunopathology with prominent perivascular lymphocytic cuffing and multifocal involvement at terminal airways (40x, H E). (C) IN vaccination shows pulmonary pathology characterized by a combination of interstitial pneumonia and immunopathology (40x, H E). (D) Foci of interstitial pneumonia are characterized by prominent type II pneumocyte hyperplasia, leukocyte infiltration and expansion of alveolar septa and accumulation of low numbers of macrophages, neutrophils and proteinaceous fluid in alveolar spaces (200x, H E). (E) Terminal airways and medium to small caliber blood vessels are cuffed by moderate numbers of lymphocytes with scattered eosinophils (200x, H E). (F) Foci of interstitial pneumonia show pronounced type II pneumocyte hyperplasia, thickening of alveolar septa by an infiltration of leukocytes and leukocyte spillover into adjacent alveolar spaces with moderate numbers of alveolar eosinophils noted and multifocal fibrin mats filling alveolar spaces (200x, H E). (G) Low numbers of type I pneumocytes in regions lacking pathology are immunoreactive for <t>SARS-CoV-2</t> antibody (200x, immunohistochemistry (IHC)). (H) SARS-CoV-2-specific immunoreactivity was not observed in evaluated sections of the IM vaccinated group (200x, IHC). (I) Low numbers of type I pneumocytes and alveolar macrophages are immunoreactive for SARS-CoV-2 in select foci of interstitial pneumonia (200x, IHC).
    Sars Cov 2 Rbd, supplied by Sino Biological, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars cov 2 rbd/product/Sino Biological
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 rbd - by Bioz Stars, 2021-06
    97/100 stars
      Buy from Supplier

    86
    Sino Biological sars cov 2 2019 ncov spike rbd antibody rabbit pab
    CVnCoV induces humoral response in non-human primates. (A) Schematic drawing of study setup. Rhesus macaques (n=6; 3 male, 3 female/group) were vaccinated IM on day 0 and day 28 with 0.5 μg or 8 μg of CVnCoV or remained unvaccinated. All animals were challenge with 5.0 x 106 PFU of <t>SARS-CoV-2</t> on d56. Two animals of each group were terminated on d62, d63 and d64, respectively (B) Trimeric Spike protein or (C) RBD specific binding IgG antibodies, displayed as endpoint titres at different time points as indicated (C) Virus neutralising antibodies determined via focus reduction neutralisation test at different time points as indicated. All values are displayed as median with range. Square symbols represent male, round symbols female animals. Dotted lines represent vaccinations and challenge infection, respectively. RBD receptor binding domain; VNT virus neutralising titre
    Sars Cov 2 2019 Ncov Spike Rbd Antibody Rabbit Pab, supplied by Sino Biological, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars cov 2 2019 ncov spike rbd antibody rabbit pab/product/Sino Biological
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 2019 ncov spike rbd antibody rabbit pab - by Bioz Stars, 2021-06
    86/100 stars
      Buy from Supplier

    96
    Sino Biological sars cov 2 2019 ncov spike rbd mfc recombinant protein hplc verified covid 19 spike rbd research
    CVnCoV induces humoral response in non-human primates. (A) Schematic drawing of study setup. Rhesus macaques (n=6; 3 male, 3 female/group) were vaccinated IM on day 0 and day 28 with 0.5 μg or 8 μg of CVnCoV or remained unvaccinated. All animals were challenge with 5.0 x 106 PFU of <t>SARS-CoV-2</t> on d56. Two animals of each group were terminated on d62, d63 and d64, respectively (B) Trimeric Spike protein or (C) RBD specific binding IgG antibodies, displayed as endpoint titres at different time points as indicated (C) Virus neutralising antibodies determined via focus reduction neutralisation test at different time points as indicated. All values are displayed as median with range. Square symbols represent male, round symbols female animals. Dotted lines represent vaccinations and challenge infection, respectively. RBD receptor binding domain; VNT virus neutralising titre
    Sars Cov 2 2019 Ncov Spike Rbd Mfc Recombinant Protein Hplc Verified Covid 19 Spike Rbd Research, supplied by Sino Biological, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sars cov 2 2019 ncov spike rbd mfc recombinant protein hplc verified covid 19 spike rbd research/product/Sino Biological
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    sars cov 2 2019 ncov spike rbd mfc recombinant protein hplc verified covid 19 spike rbd research - by Bioz Stars, 2021-06
    96/100 stars
      Buy from Supplier

    Image Search Results


    Histopathology and Immunohistochemistry of NHP lungs. (A) Pulmonary lesions depicting typical coronavirus respiratory pathology including locally extensive regions of bronchointerstitial pneumonia and proteinaceous fluid accumulation in adjacent alveoli (40x, H E). (B) Disseminated immunopathology with prominent perivascular lymphocytic cuffing and multifocal involvement at terminal airways (40x, H E). (C) IN vaccination shows pulmonary pathology characterized by a combination of interstitial pneumonia and immunopathology (40x, H E). (D) Foci of interstitial pneumonia are characterized by prominent type II pneumocyte hyperplasia, leukocyte infiltration and expansion of alveolar septa and accumulation of low numbers of macrophages, neutrophils and proteinaceous fluid in alveolar spaces (200x, H E). (E) Terminal airways and medium to small caliber blood vessels are cuffed by moderate numbers of lymphocytes with scattered eosinophils (200x, H E). (F) Foci of interstitial pneumonia show pronounced type II pneumocyte hyperplasia, thickening of alveolar septa by an infiltration of leukocytes and leukocyte spillover into adjacent alveolar spaces with moderate numbers of alveolar eosinophils noted and multifocal fibrin mats filling alveolar spaces (200x, H E). (G) Low numbers of type I pneumocytes in regions lacking pathology are immunoreactive for SARS-CoV-2 antibody (200x, immunohistochemistry (IHC)). (H) SARS-CoV-2-specific immunoreactivity was not observed in evaluated sections of the IM vaccinated group (200x, IHC). (I) Low numbers of type I pneumocytes and alveolar macrophages are immunoreactive for SARS-CoV-2 in select foci of interstitial pneumonia (200x, IHC).

    Journal: bioRxiv

    Article Title: Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine

    doi: 10.1101/2021.01.19.426885

    Figure Lengend Snippet: Histopathology and Immunohistochemistry of NHP lungs. (A) Pulmonary lesions depicting typical coronavirus respiratory pathology including locally extensive regions of bronchointerstitial pneumonia and proteinaceous fluid accumulation in adjacent alveoli (40x, H E). (B) Disseminated immunopathology with prominent perivascular lymphocytic cuffing and multifocal involvement at terminal airways (40x, H E). (C) IN vaccination shows pulmonary pathology characterized by a combination of interstitial pneumonia and immunopathology (40x, H E). (D) Foci of interstitial pneumonia are characterized by prominent type II pneumocyte hyperplasia, leukocyte infiltration and expansion of alveolar septa and accumulation of low numbers of macrophages, neutrophils and proteinaceous fluid in alveolar spaces (200x, H E). (E) Terminal airways and medium to small caliber blood vessels are cuffed by moderate numbers of lymphocytes with scattered eosinophils (200x, H E). (F) Foci of interstitial pneumonia show pronounced type II pneumocyte hyperplasia, thickening of alveolar septa by an infiltration of leukocytes and leukocyte spillover into adjacent alveolar spaces with moderate numbers of alveolar eosinophils noted and multifocal fibrin mats filling alveolar spaces (200x, H E). (G) Low numbers of type I pneumocytes in regions lacking pathology are immunoreactive for SARS-CoV-2 antibody (200x, immunohistochemistry (IHC)). (H) SARS-CoV-2-specific immunoreactivity was not observed in evaluated sections of the IM vaccinated group (200x, IHC). (I) Low numbers of type I pneumocytes and alveolar macrophages are immunoreactive for SARS-CoV-2 in select foci of interstitial pneumonia (200x, IHC).

    Article Snippet: NUNC Maxisorp Immuno plates were coated with 50 μl of 1 μg/mL of recombinant SARS-CoV-2 spike (S1+S2), SARS-CoV-2 RBD (Sino Biological) or EBOV GP antigen at 4°C overnight and then washed three times with phosphate buffer saline containing 0.05% Tween 20 (PBST).

    Techniques: Histopathology, Immunohistochemistry

    Schematic and characterization of VSV-based vaccines. (A) Schematic illustrating vaccine vector design. T7 promotor; N nucleoprotein; P phosphoprotein; M matrix protein; EBOV GP Ebola virus glycoprotein; L RNA-dependent RNA polymerase; SARS2-S SARS-CoV-2 S. (B) Western blot analysis of cell supernatant samples containing VSV vaccines probed for SARS-CoV-2 S (left), VSV M (middle) or EBOV GP (right). 1 VSV wildtype (VSVwt); 2 VSV-EBOV; 3 VSV-SARS2-EBOV. (C) Viral growth kinetics on VeroE6 cells. Geometric mean and SD are depicted. Results are not statistically significant. (D) Schematic outline of the rhesus macaque study.

    Journal: bioRxiv

    Article Title: Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine

    doi: 10.1101/2021.01.19.426885

    Figure Lengend Snippet: Schematic and characterization of VSV-based vaccines. (A) Schematic illustrating vaccine vector design. T7 promotor; N nucleoprotein; P phosphoprotein; M matrix protein; EBOV GP Ebola virus glycoprotein; L RNA-dependent RNA polymerase; SARS2-S SARS-CoV-2 S. (B) Western blot analysis of cell supernatant samples containing VSV vaccines probed for SARS-CoV-2 S (left), VSV M (middle) or EBOV GP (right). 1 VSV wildtype (VSVwt); 2 VSV-EBOV; 3 VSV-SARS2-EBOV. (C) Viral growth kinetics on VeroE6 cells. Geometric mean and SD are depicted. Results are not statistically significant. (D) Schematic outline of the rhesus macaque study.

    Article Snippet: NUNC Maxisorp Immuno plates were coated with 50 μl of 1 μg/mL of recombinant SARS-CoV-2 spike (S1+S2), SARS-CoV-2 RBD (Sino Biological) or EBOV GP antigen at 4°C overnight and then washed three times with phosphate buffer saline containing 0.05% Tween 20 (PBST).

    Techniques: Plasmid Preparation, Western Blot

    Humoral immune responses in NHPs. Serum samples collected throughout the study from all NHPs were examined for (A) SARS-CoV-2 S-specific IgG, (B) SARS-CoV-2 S receptor binding domain (RBD)-specific IgG or (C) IgG subclasses specific to SARS-CoV-2 S by ELISA. (D) Neutralizing titers to SARS-CoV-2 were determined. (E) Bronchoalveolar lavage (BAL) samples were analyzed for SARS-CoV-2 S-specific IgG (S IgG) or IgA (S IgA), and SARS CoV-2 S RBD-specific IgG (RBD IgG) by ELISA. (A-D) Geometric mean and geometric standard deviation (SD) are depicted. (F) IgG subclasses specific to SARS-CoV-2 S in BAL samples were analyzed by ELISA. (E, F) Mean and SD are depicted. Statistical significance is indicated.

    Journal: bioRxiv

    Article Title: Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine

    doi: 10.1101/2021.01.19.426885

    Figure Lengend Snippet: Humoral immune responses in NHPs. Serum samples collected throughout the study from all NHPs were examined for (A) SARS-CoV-2 S-specific IgG, (B) SARS-CoV-2 S receptor binding domain (RBD)-specific IgG or (C) IgG subclasses specific to SARS-CoV-2 S by ELISA. (D) Neutralizing titers to SARS-CoV-2 were determined. (E) Bronchoalveolar lavage (BAL) samples were analyzed for SARS-CoV-2 S-specific IgG (S IgG) or IgA (S IgA), and SARS CoV-2 S RBD-specific IgG (RBD IgG) by ELISA. (A-D) Geometric mean and geometric standard deviation (SD) are depicted. (F) IgG subclasses specific to SARS-CoV-2 S in BAL samples were analyzed by ELISA. (E, F) Mean and SD are depicted. Statistical significance is indicated.

    Article Snippet: NUNC Maxisorp Immuno plates were coated with 50 μl of 1 μg/mL of recombinant SARS-CoV-2 spike (S1+S2), SARS-CoV-2 RBD (Sino Biological) or EBOV GP antigen at 4°C overnight and then washed three times with phosphate buffer saline containing 0.05% Tween 20 (PBST).

    Techniques: Binding Assay, Enzyme-linked Immunosorbent Assay, Standard Deviation

    BAL RNA-sequencing. (A) Venn diagram of differentially expressed genes (DEGs) expressed 3 days post challenge with SARS-CoV-2. Animals either received a control, intramuscular (IM) or intranasal (IN) vaccination. (B) Bubbleplot representing functional enrichment of DEGs shared by all infected groups at 3 days post challenge. Color intensity of each bubble represents the negative log of p-value and the relative size of each bubble represents the number of DEGs belonging to the specified Gene Ontology (GO) term. (C) Heatmap representing shared upregulated DEGs enriching to GO terms “lymphocyte activation” and “T cell differentiation in volved in the immune response.” Expression is represented as the normalized rpkm, where each column represents the median rpkm of the given group. Range of colors is based on scale and centered rpkm values of the represented DEGs. GO term network depicting functional enrichment of DEGs unique to (D) IN and (F) IM using Mediascape. Color-coded clustered nodes correspond to one GO term or KEGG pathway. Node size represents the number of DEGs associated with the indicated term or pathway. Gray lines represent shared interactions between terms/pathways, with density and number indicating the strength of connections between closely related terms/pathways. Heatmaps representing DEGs unique to (E) IN and (G) IM. Exemplar DEGs are annotated. Red represents upregulation, blue presents downregulation. Each column represents the median rpkm of the given group. For all heatmaps, range of colors is based on scale and centered rpkm values of the represented DEGs.

    Journal: bioRxiv

    Article Title: Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine

    doi: 10.1101/2021.01.19.426885

    Figure Lengend Snippet: BAL RNA-sequencing. (A) Venn diagram of differentially expressed genes (DEGs) expressed 3 days post challenge with SARS-CoV-2. Animals either received a control, intramuscular (IM) or intranasal (IN) vaccination. (B) Bubbleplot representing functional enrichment of DEGs shared by all infected groups at 3 days post challenge. Color intensity of each bubble represents the negative log of p-value and the relative size of each bubble represents the number of DEGs belonging to the specified Gene Ontology (GO) term. (C) Heatmap representing shared upregulated DEGs enriching to GO terms “lymphocyte activation” and “T cell differentiation in volved in the immune response.” Expression is represented as the normalized rpkm, where each column represents the median rpkm of the given group. Range of colors is based on scale and centered rpkm values of the represented DEGs. GO term network depicting functional enrichment of DEGs unique to (D) IN and (F) IM using Mediascape. Color-coded clustered nodes correspond to one GO term or KEGG pathway. Node size represents the number of DEGs associated with the indicated term or pathway. Gray lines represent shared interactions between terms/pathways, with density and number indicating the strength of connections between closely related terms/pathways. Heatmaps representing DEGs unique to (E) IN and (G) IM. Exemplar DEGs are annotated. Red represents upregulation, blue presents downregulation. Each column represents the median rpkm of the given group. For all heatmaps, range of colors is based on scale and centered rpkm values of the represented DEGs.

    Article Snippet: NUNC Maxisorp Immuno plates were coated with 50 μl of 1 μg/mL of recombinant SARS-CoV-2 spike (S1+S2), SARS-CoV-2 RBD (Sino Biological) or EBOV GP antigen at 4°C overnight and then washed three times with phosphate buffer saline containing 0.05% Tween 20 (PBST).

    Techniques: RNA Sequencing Assay, Functional Assay, Infection, Activation Assay, Cell Differentiation, Expressing

    Lung RNA-Sequencing. (A) Venn diagram of differentially expressed genes (DEGs) expressed 3 days post challenge with SARS-CoV-2. Animals either received a control, intramuscular (IM) or intranasal (IN) vaccination. (B) Bubbleplot representing functional enrichment of DEGs shared by all infected groups at 7 days post challenge. Color intensity of each bubble represents the negative log of p-value and the relative size of each bubble represents the number of DEGs belonging to the specified Gene Ontology (GO) term. Heatmaps representing shared GO terms (C) “regulation of innate immune response”, “antigen processing and presentation of exogenous antigen” for downregulated DEGs; and (D) “regulated exocytosis”, “myeloid leukocyte activation” and “neutrophil degranulation” for upregulated DEGs. Expression is represented as the normalized rpkm, where each column represents the median rpkm of the given group. Range of colors is based on scale and centered rpkm values of the represented DEGs. GO term network depicting functional enrichment of DEGs unique to (E) IN and (G) IM using Mediascape. Color-coded clustered nodes correspond to one GO term or KEGG pathway. Node size represents the number of DEGs associated with the indicated term or pathway. Gray lines represent shared interactions between terms/pathways, with density and number indicating the strength of connections between closely related terms/pathways. Heatmaps representing DEGs unique to (F) IN and (H) IM. Exemplar DEGs are annotated. Red represents upregulation, blue presents downregulation. Each column represents the median rpkm of the given group. For all heatmaps, range of colors is based on scale and centered rpkm values of the represented DEGs.

    Journal: bioRxiv

    Article Title: Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine

    doi: 10.1101/2021.01.19.426885

    Figure Lengend Snippet: Lung RNA-Sequencing. (A) Venn diagram of differentially expressed genes (DEGs) expressed 3 days post challenge with SARS-CoV-2. Animals either received a control, intramuscular (IM) or intranasal (IN) vaccination. (B) Bubbleplot representing functional enrichment of DEGs shared by all infected groups at 7 days post challenge. Color intensity of each bubble represents the negative log of p-value and the relative size of each bubble represents the number of DEGs belonging to the specified Gene Ontology (GO) term. Heatmaps representing shared GO terms (C) “regulation of innate immune response”, “antigen processing and presentation of exogenous antigen” for downregulated DEGs; and (D) “regulated exocytosis”, “myeloid leukocyte activation” and “neutrophil degranulation” for upregulated DEGs. Expression is represented as the normalized rpkm, where each column represents the median rpkm of the given group. Range of colors is based on scale and centered rpkm values of the represented DEGs. GO term network depicting functional enrichment of DEGs unique to (E) IN and (G) IM using Mediascape. Color-coded clustered nodes correspond to one GO term or KEGG pathway. Node size represents the number of DEGs associated with the indicated term or pathway. Gray lines represent shared interactions between terms/pathways, with density and number indicating the strength of connections between closely related terms/pathways. Heatmaps representing DEGs unique to (F) IN and (H) IM. Exemplar DEGs are annotated. Red represents upregulation, blue presents downregulation. Each column represents the median rpkm of the given group. For all heatmaps, range of colors is based on scale and centered rpkm values of the represented DEGs.

    Article Snippet: NUNC Maxisorp Immuno plates were coated with 50 μl of 1 μg/mL of recombinant SARS-CoV-2 spike (S1+S2), SARS-CoV-2 RBD (Sino Biological) or EBOV GP antigen at 4°C overnight and then washed three times with phosphate buffer saline containing 0.05% Tween 20 (PBST).

    Techniques: RNA Sequencing Assay, Functional Assay, Infection, Activation Assay, Expressing

    CVnCoV induces humoral response in non-human primates. (A) Schematic drawing of study setup. Rhesus macaques (n=6; 3 male, 3 female/group) were vaccinated IM on day 0 and day 28 with 0.5 μg or 8 μg of CVnCoV or remained unvaccinated. All animals were challenge with 5.0 x 106 PFU of SARS-CoV-2 on d56. Two animals of each group were terminated on d62, d63 and d64, respectively (B) Trimeric Spike protein or (C) RBD specific binding IgG antibodies, displayed as endpoint titres at different time points as indicated (C) Virus neutralising antibodies determined via focus reduction neutralisation test at different time points as indicated. All values are displayed as median with range. Square symbols represent male, round symbols female animals. Dotted lines represent vaccinations and challenge infection, respectively. RBD receptor binding domain; VNT virus neutralising titre

    Journal: bioRxiv

    Article Title: mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection

    doi: 10.1101/2020.12.23.424138

    Figure Lengend Snippet: CVnCoV induces humoral response in non-human primates. (A) Schematic drawing of study setup. Rhesus macaques (n=6; 3 male, 3 female/group) were vaccinated IM on day 0 and day 28 with 0.5 μg or 8 μg of CVnCoV or remained unvaccinated. All animals were challenge with 5.0 x 106 PFU of SARS-CoV-2 on d56. Two animals of each group were terminated on d62, d63 and d64, respectively (B) Trimeric Spike protein or (C) RBD specific binding IgG antibodies, displayed as endpoint titres at different time points as indicated (C) Virus neutralising antibodies determined via focus reduction neutralisation test at different time points as indicated. All values are displayed as median with range. Square symbols represent male, round symbols female animals. Dotted lines represent vaccinations and challenge infection, respectively. RBD receptor binding domain; VNT virus neutralising titre

    Article Snippet: Following washing with water using an ELISA washer (BioTek 405 TSUS), residual endogenous peroxidase activity was removed by the addition of 0.3% hydrogen peroxide for 20 min. Plates were then incubated for 1 h with primary/detection SARS-CoV-2 anti-RBD rabbit polyclonal antibody (SinoBiologicals; 40592-T62) diluted 1: 2,000 in PBS.

    Techniques: Binding Assay, Infection

    Exemplary sections showing histopathology (H E) and SARS-CoV-2 in situ hybridisation (ISH). A. Alveolar necrosis and inflammatory exudates (*) in the alveolar spaces and type II pneumocyte hyperplasia (arrows). B) Mild perivascular cuffing (arrow). C) Inflammatory cell infiltration in the alveolar spaces and the interalveolar septa (*) and type II pneumocyte hyperplasia (arrows). D) SARS-CoV-2 ISH staining in abundant cell within inflammatory foci (arrows). E. SARS-CoV-2 ISH staining in a single cell within an interalveolar septum (arrow). F. Abundant foci of SARS-CoV-2 ISH stained cells within the alveolar lining and the interalveolar septa (arrows). Bar = 100μm. ISH in situ hybridisation

    Journal: bioRxiv

    Article Title: mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection

    doi: 10.1101/2020.12.23.424138

    Figure Lengend Snippet: Exemplary sections showing histopathology (H E) and SARS-CoV-2 in situ hybridisation (ISH). A. Alveolar necrosis and inflammatory exudates (*) in the alveolar spaces and type II pneumocyte hyperplasia (arrows). B) Mild perivascular cuffing (arrow). C) Inflammatory cell infiltration in the alveolar spaces and the interalveolar septa (*) and type II pneumocyte hyperplasia (arrows). D) SARS-CoV-2 ISH staining in abundant cell within inflammatory foci (arrows). E. SARS-CoV-2 ISH staining in a single cell within an interalveolar septum (arrow). F. Abundant foci of SARS-CoV-2 ISH stained cells within the alveolar lining and the interalveolar septa (arrows). Bar = 100μm. ISH in situ hybridisation

    Article Snippet: Following washing with water using an ELISA washer (BioTek 405 TSUS), residual endogenous peroxidase activity was removed by the addition of 0.3% hydrogen peroxide for 20 min. Plates were then incubated for 1 h with primary/detection SARS-CoV-2 anti-RBD rabbit polyclonal antibody (SinoBiologicals; 40592-T62) diluted 1: 2,000 in PBS.

    Techniques: Histopathology, In Situ, Hybridization, In Situ Hybridization, Staining